New depression drug shows promise in early trials

NCT ID NCT03726658

Completed Symptom relief Sponsor: Syndeio Biosciences, Inc Source: ClinicalTrials.gov ↗

First seen Apr 11, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study tested an experimental drug called AGN-241751 in 226 adults with major depressive disorder. The goal was to see if the drug could safely reduce depression symptoms better than a placebo. Participants received either the drug or a placebo, and their depression levels were measured using a standard rating scale over several weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alea Research

Phoenix, Arizona, 85012, United States
Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States
Collaborative Neuroscience Network, LLC

Garden Grove, California, 92845, United States
Hassman Research Institute

Berlin, New Jersey, 08809, United States
Northwest Clinical Research Center

Bellevue, Washington, 98007, United States

Conditions

Explore the condition pages connected to this study.

MAJOR DEPRESSIVE DISORDER